(Q37337947)

19 August 2017

1 reference

title

Botulinum neurotoxins in the treatment of refractory pain (English)

1 reference

19 August 2017

Bahman Jabbari

1

1 reference

19 August 2017

publication date

1 December 2008

1 reference

Nature Clinical Practice Neurology

19 August 2017

published in

1 reference

19 August 2017

volume

4

1 reference

19 August 2017

issue

12

1 reference

19 August 2017

page(s)

676-685

1 reference

Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

Botulinum toxin A and chronic low back pain: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

Recognizing and treating pelvic pain and pelvic floor dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Evidence for antinociceptive activity of botulinum toxin type A in pain management

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum A toxin effects on rat jaw muscle spindles

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Subcutaneous administration of botulinum toxin A reduces formalin-induced pain

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis: a molecular mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Impairment of Sympathetic Transmission by Botulinum Toxin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

The treatment of cervical dystonia with botulinum toxins

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in 37 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

The role of headache-related disability in migraine management: implications for headache treatment guidelines

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Evidence based medicine on the use of botulinum toxin for headache disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin type A for the treatment of headache: why we say yes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache - a multicentre, double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

A double-blind, controlled study of botulinum toxin A in chronic myofascial pain

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Therapeutic use of botulinum toxin type A in treating neck and upper-back pain of myofascial origin: a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

BOTOX and physical therapy in the treatment of piriformis syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Treatment of pain attributed to plantar fasciitis with botulinum toxin a: a short-term, randomized, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

A focused review on the use of botulinum toxins for neuropathic pain

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Botulinum toxin (botox) reduces pain after hemorrhoidectomy: results of a double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0948

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0948

1 reference

19 August 2017

1 reference